Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
03/03/2025 14:18
March 3 (Reuters) - Nkgen Biotech Inc NKGN.O: NKGEN BIOTECH ANNOUNCES ADMINISTRATION OF FIRST DOSE OF TROCULEUCEL TO STROKE PATIENT UNDER FDA-CLEARED COMPASSIONATE USE PROGRAM Source text: ID:nGNX4k4GY1 Further company coverage: NKGN.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program